Aspirin Use in Chronic Kidney Disease Not Linked to Major CV Event Reduction
What happened
A clinical trial examining the ATTACK cohort found that low-dose aspirin did not significantly reduce risks for major cardiovascular events compared to usual care in patients with chronic kidney disease. Hugh Gallagher, a consultant nephrologist, stated that the safety and efficacy of aspirin as a primary preventive measure in this population is not clear. He added that the balance between benefits and harms depends on the patient's baseline risk.
From healio.com
Why it matters
The findings challenge current medical protocols regarding primary prevention in chronic kidney disease. Since the primary interventions for preventing cardiovascular events in CKD are limited to lipid-lowering therapies and SGLT2 inhibitors, this research may influence prescribing guidelines for cardiovascular drugs in the U.K.
From healio.com
Who's involved
- Hugh GallagherConsultant nephrologist involved in the clinical trial
- U.K.Geographical location where the trial took place
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Aspirin trial results may change CKD treatment guidelines in EnglandAspirin trial results may prompt changes to CKD treatment protocols in England.Possible
- How could the nephrology trial on aspirin use affect Keir Starmer?The government may need to update national health policies and resource allocation based on the new clinical evidence regarding drug efficacy.Possible
Keep exploring
The entities involved
-
Hugh Gallagher
researcher
Nothing else this week.
-
Epsom
town in Surrey, England, United Kingdom
- U.K.